Benzinga’s Top Ratings Upgrades, Downgrades For June 5, 2023
Upgrades According to Citigroup, the prior rating for Ford Motor Co (NYSE:F) was changed from Neutral to Buy.…
Why Guidewire Software Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Friday’s Mid-Day Session
Gainers
MultiMetaVerse Holdings Limited (NASDAQ: MMV) gained 236% to $3.1592 after the company announced it signed a non-binding term sheet to acquire an equity stake in Taomee group.
12 Health Care Stocks Moving In Friday’s Pre-Market Session
Gainers Connect Biopharma Hldgs (NASDAQ:CNTB) stock rose 44.1% to $1.6 during Friday’s pre-market session. The market value of…
Why Lululemon Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
Gainers
Better Choice Company Inc. (NASDAQ: BTTR) shares rose 37% to $0.4522 in pre-market trading. Better Choice said it has selected Re:Amaze to assist in customer retention and acquisition for its Halo Brand of dog and cat food.
Over $4M Bet On Diversified Healthcare Trust? Check Out These 4 Stocks Under $5 Insiders Are Aggressively Buying
The Dow Jones closed higher by around 150 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
12 Health Care Stocks Moving In Thursday’s After-Market Session
Gainers Bluejay Diagnostics (NASDAQ:BJDX) shares increased by 23.6% to $0.28 during Thursday’s after-market session. At the close, Bluejay…
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's morning session, 137 companies made new 52-week lows.
Rain Oncology Provides Company Update And Outlines Strategic Priorities Of Milademetan Clinical Programs; Workforce Reduction Of ~65% Of The Company’s Employees; With A Transition Of Chief Medical Officer Responsibilities
– Company plans to suspend enrollment in the ongoing milademetan Phase 2 MANTRA-2 basket trial and terminate plans for its Phase 1/2 MANTRA-4 combination trial –
– Evaluation of outcomes from
Analyst Expectations for Rain Oncology’s Future
Within the last quarter, Rain Oncology (NASDAQ:RAIN) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…